The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Exploring the association between PFS and OS in patients with R/R MM from a real-world perspective
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the association between progression-free survival (PFS) and overall survival (OS) in patients with relapsed/refractory multiple myeloma (R/R MM) receiving 2-4 lines of therapy, highlighting that achieving PFS can improve OS in this patient population. Dr Ramasamy notes that real-world data from registries such as PREAMBLE and the Flatiron database are being used to demonstrate this link, which will give clinicians, patients, and regulators confidence to use PFS as an endpoint to approve and access new therapies. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There’s been an ongoing challenge around whether reading out progression-free survival is going to truly mark out an improvement in overall survival in trials which show an earlier improvement in PFS. We’re starting to understand the link between PFS and overall survival better but in the real world there’s been not much in the way of data and what we’re currently doing is using registries such as PREAMBLE and also Flatiron database...
There’s been an ongoing challenge around whether reading out progression-free survival is going to truly mark out an improvement in overall survival in trials which show an earlier improvement in PFS. We’re starting to understand the link between PFS and overall survival better but in the real world there’s been not much in the way of data and what we’re currently doing is using registries such as PREAMBLE and also Flatiron database. We are looking at whether progression-free survival really translates to improved overall survival and using the set of features which define relapsed/refractory myeloma, we are able to demonstrate that achieving a progression-free survival can improve overall survival in this patient population. So how is this going to be useful? We’re going to have more and more therapies which are going to be reading out with the progression-free survival outcome, and this will give both practicing clinicians, patients, and regulators more confidence to be able to use PFS as an endpoint to approve and give access to these agents for patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
